CTOs on the Move

Megadyne Medical Products

www.megadyne.com

 
Megadyne Medical Products is a Draper, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Med South

Med South is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Warner Tech-Care Products

Warner Tech-Care Products, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioject

Bioject Medical Technologies Inc. is a leader in the development of needle-free injection therapies with over 25 years of experience improving the administration of liquid medications; pharmaceuticals, vaccines, and biologics. Bioject's technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. This creates an ultra-fine stream of fluid that penetrates the skin, delivering medication in a fraction of a second. Bioject's systems are designed to deliver injected medications comfortably, accurately, and quickly - without the use of a needle. Bioject was founded in 1985 to develop needle-free injection systems to improve the comfort and safety of routine injections. From its early work focused on improving the characteristics of these delivery systems, the Company has created a broad technology platform for delivering a wide range of medications and vaccines to the subcutaneous, intramuscular and intradermal depths. Bioject has developed a portfolio of injection systems based on its core technology, the foundation for which is more than 80 issued and pending patents and an extensive body of technical know-how. These include durable devices designed for heavy use in a professional healthcare environment, and small, lightweight injectors designed for home use. With partners, Bioject is also developing inexpensive, pre-filled, disposable injection systems. Further validating its technology, Bioject and its partners have the largest volume of published studies using needle-free injection technology systems. Bioject's strategy is to form strategic partnerships with pharmaceutical, biotechnology, and animal health companies. The result is mutually beneficial agreements with these partners to develop customized injection systems to enhance the delivery of their injected medication or vaccine. Bioject has alliances with leading pharmaceutical, biotechnology, and animal health companies. Bioject's products are also used in public health, Physicians offices, and in cutting edge biomedical research at leading institutions around the globe.  

r4 Vascular

r4 Vascular, Inc. is a Maple Grove, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insulet

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet`s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.